-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, many well-known pharmaceutical companies are seeking to go public
.
For example, a few days ago, Condini Pharmaceuticals, a pharmaceutical company focusing on rare diseases, submitted a prospectus to the Hong Kong Stock Exchange and plans to list in Hong Kong
.
It is reported that the pharmaceutical company has launched two sprints before, but both failed to pass the listing hearing
.
According to public information, Beijing Kangdini Pharmaceutical Co.
, Ltd.
("Kantini Pharmaceutical") is an enterprise focusing on the development, manufacture and distribution of drugs for the treatment of organ fibrosis and other rare and critical diseases
.
Compared with many Biotechs currently listed in Hong Kong stocks, Condini Pharmaceuticals has already launched products on the market and has generated considerable sales revenue
.
Aspirin, the flagship product of Condini Pharmaceuticals, was approved in China in 2011 and has been included in the National Medical Insurance Catalogue since 2017
.
According to data, the market size of China's IPF treatment in 2020 is 478 million yuan, while the total disclosed revenue of Aisi Rui is 437 million yuan, accounting for 91.
4% of the market share
.
It is worth mentioning that Esery is currently expanding its indications to other pulmonary fibrosis diseases, including systemic sclerosis-related interstitial lung disease (SSc-ILD) and dermatomyositis-related interstitial lung disease (DM-ILD).
, pneumoconiosis and diseases that lead to renal fibrosis
.
It is worth mentioning that, in addition to Essery, Condini Pharmaceuticals has also built a pipeline of products under development for liver fibrosis, chronic obstructive pulmonary disease, pulmonary hypertension, and acute and acute-on-chronic liver failure
.
In fact, since the Hong Kong Stock Exchange revised the "Listing Rules" in 2018 to introduce Chapter 18A, allowing unprofitable biotech companies to list in Hong Kong, China, there has been an upsurge in the listing of pharmaceutical and medical companies in Hong Kong
.
It is reported that on February 28, the Hong Kong Stock Exchange disclosed that Zhiyun Health Technology Group (“Zhiyun Health”) also submitted a listing application to the main board of the Hong Kong Stock Exchange again, with Morgan Stanley and JPMorgan Chase as the joint sponsors
.
In fact, on August 27, 2021, Zhiyun Health also submitted a listing application form to the Hong Kong Stock Exchange
.
On February 25th, Supai Health Technology Co.
, Ltd.
(hereinafter referred to as "Supai Health") also publicly submitted a prospectus on the Hong Kong Stock Exchange again, preparing to be listed on the main board of the Hong Kong Stock Exchange.
This is also the second submission of Supai Health
.
In addition, as of January 6, 2022, the IPO applications for innovative drugs on the main board of the Hong Kong Stock Exchange have already been processed by 8 innovative drug companies, including Sidi Medicine, Ruike Bio, Tianguangshi, and Amy Vaccines.
, Biositu, Arno Medicine, Yaojie Ankang, Lepu Bio, mainly focusing on tumor, autoimmunity, vaccine and other fields
.
Regarding the situation that a large number of companies have successively listed in Hong Kong, industry insiders believe that this is mainly due to the high research and development costs of pharmaceutical companies and the strong uncertainty of future development, so they need strong capital assistance to promote the company's development
.
Due to the faster listing speed of Hong Kong stocks, many companies have chosen to list in Hong Kong
.
The industry expects that for a long time in the future, the listing of innovative drug companies in Hong Kong may be the mainstream
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
For example, a few days ago, Condini Pharmaceuticals, a pharmaceutical company focusing on rare diseases, submitted a prospectus to the Hong Kong Stock Exchange and plans to list in Hong Kong
.
It is reported that the pharmaceutical company has launched two sprints before, but both failed to pass the listing hearing
.
According to public information, Beijing Kangdini Pharmaceutical Co.
, Ltd.
("Kantini Pharmaceutical") is an enterprise focusing on the development, manufacture and distribution of drugs for the treatment of organ fibrosis and other rare and critical diseases
.
Compared with many Biotechs currently listed in Hong Kong stocks, Condini Pharmaceuticals has already launched products on the market and has generated considerable sales revenue
.
Aspirin, the flagship product of Condini Pharmaceuticals, was approved in China in 2011 and has been included in the National Medical Insurance Catalogue since 2017
.
According to data, the market size of China's IPF treatment in 2020 is 478 million yuan, while the total disclosed revenue of Aisi Rui is 437 million yuan, accounting for 91.
4% of the market share
.
It is worth mentioning that Esery is currently expanding its indications to other pulmonary fibrosis diseases, including systemic sclerosis-related interstitial lung disease (SSc-ILD) and dermatomyositis-related interstitial lung disease (DM-ILD).
, pneumoconiosis and diseases that lead to renal fibrosis
.
It is worth mentioning that, in addition to Essery, Condini Pharmaceuticals has also built a pipeline of products under development for liver fibrosis, chronic obstructive pulmonary disease, pulmonary hypertension, and acute and acute-on-chronic liver failure
.
In fact, since the Hong Kong Stock Exchange revised the "Listing Rules" in 2018 to introduce Chapter 18A, allowing unprofitable biotech companies to list in Hong Kong, China, there has been an upsurge in the listing of pharmaceutical and medical companies in Hong Kong
.
It is reported that on February 28, the Hong Kong Stock Exchange disclosed that Zhiyun Health Technology Group (“Zhiyun Health”) also submitted a listing application to the main board of the Hong Kong Stock Exchange again, with Morgan Stanley and JPMorgan Chase as the joint sponsors
.
In fact, on August 27, 2021, Zhiyun Health also submitted a listing application form to the Hong Kong Stock Exchange
.
On February 25th, Supai Health Technology Co.
, Ltd.
(hereinafter referred to as "Supai Health") also publicly submitted a prospectus on the Hong Kong Stock Exchange again, preparing to be listed on the main board of the Hong Kong Stock Exchange.
This is also the second submission of Supai Health
.
In addition, as of January 6, 2022, the IPO applications for innovative drugs on the main board of the Hong Kong Stock Exchange have already been processed by 8 innovative drug companies, including Sidi Medicine, Ruike Bio, Tianguangshi, and Amy Vaccines.
, Biositu, Arno Medicine, Yaojie Ankang, Lepu Bio, mainly focusing on tumor, autoimmunity, vaccine and other fields
.
Regarding the situation that a large number of companies have successively listed in Hong Kong, industry insiders believe that this is mainly due to the high research and development costs of pharmaceutical companies and the strong uncertainty of future development, so they need strong capital assistance to promote the company's development
.
Due to the faster listing speed of Hong Kong stocks, many companies have chosen to list in Hong Kong
.
The industry expects that for a long time in the future, the listing of innovative drug companies in Hong Kong may be the mainstream
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
